This Under-$10 Growth Stock May Be Better Positioned Than Investors Realize

Core Viewpoint - Tilray Brands (TLRY) is positioned as a diversified global platform in the cannabis industry, with operations extending beyond just cannabis to include pharmaceuticals, beverages, and wellness products, despite being perceived as a volatile stock trading under $10 [1][2] Financial Performance - Tilray reported its highest-ever second-quarter net revenue of $218 million, which exceeded analyst estimates and represented a 3% year-on-year increase [5] - Adjusted EBITDA for the quarter was $8.4 million, and adjusted cash operating income was positive at $6 million [5] Market Position - In Canada, Tilray maintained its market leadership across several product categories, including dried flower, pre-rolls, beverages, oils, and edibles, with adult-use and medical cannabis revenue totaling $46 million [5] - Recreational cannabis sales showed an increase during the quarter, indicating a positive trend in consumer demand [5] International Growth - Tilray operates in over 20 countries, with significant international cannabis revenue growth, which rose to $68 million, reflecting a 36% year-on-year increase and a 51% sequential increase [6] - The company's pharmacy network in Europe plays a crucial role in distributing medical cannabis and pharmaceuticals, contributing to the overall growth of the business [6] Distribution and Profitability - Tilray Pharma and its distribution business achieved a 26% year-on-year sales increase to $85 million, marking its highest quarter to date [6] - Factors contributing to this growth include competitive pricing, portfolio optimization, and increased sales of medical devices [6]